Showing results (1-10 of 45) with videos related to
Sort By:
Pageof 5
Cells|December 24, 2025
Current Status and Future Challenges of Liquid BiopsyShuta Ohara, Kenichi SudaCells|February 12, 2021
Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers-Applications and LimitationsShuta Ohara, Kenichi Suda, Tetsuya MitsudomiCells|September 13, 2025
Utility and Future Perspectives of Circulating Tumor DNA Analysis in Non-Small Cell Lung Cancer Patients in the Era of Perioperative Chemo-ImmunotherapyShuta Ohara, Kenichi Suda, Yasuhiro TsutaniClinical Lung Cancer|November 9, 2021
Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung CancerKenichi Suda, Shuta Ohara, Toshio Fujino, et al.Biomedicines|July 27, 2024
Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms-An In Vitro StudyShota Fukuda, Kenichi Suda, Akira Hamada, et al.Translational Cancer Research|November 11, 2024
Bioinformatics analysis reveals SOD1 is a prognostic factor in lung adenocarcinomaLing Gao, Wei Wang, Haishan Ma, et al.Cancer Science|September 23, 2024
Improved platelet separation performance from whole blood using an acoustic fluidics systemKazuko Sakai, Shuta Ohara, Junko Tanaka, et al.Thoracic Cancer|September 20, 2024
Clinical factors associated with high PD-L1 expression in patients with early-stage non-small cell lung cancerShuta Ohara, Kenichi Suda, Akira Hamada, et al.Journal of Hematology & Oncology|June 11, 2022
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutationToshio Fujino, Kenichi Suda, Takamasa Koga, et al.Clinical Lung Cancer|October 14, 2020
Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five CasesKenichi Suda, Kazuko Sakai, Keiko Obata, et al.Pageof 5